Medable, Inc., the leading global platform for decentralized clinical trials, and AliveCor, the leader in AI-based, personal ECG technology, today announced a partnership to dramatically scale remote clinical trials by enabling in-home ECGs with AliveCor’s KardiaMobile6L, the world’s only FDA-cleared six-lead personal ECG. As an integrated capability within the Medable platform, KardiaMobile 6L removes a key barrier to enabling in-home clinical trials.
Historically, the need for in-clinic ECGs has been a barrier to decentralized trials, as an ECG is one of the most commonly performed safety measurements in those trials. Standard ECG machines require a trained technician or nurse, which make them an obstacle for in-home testing. KardiaMobile 6L gives patients access to a self-administered, easy-to-use, medical-grade ambulatory ECG at home.
“AliveCor is the leader in patient-centric ECG. Their device has set the bar for convenient, medical-grade ECG technology, and now we will bring this capability into decentralized clinical trials,” said Dr. Michelle Longmire, CEO and co-founder of Medable. “We could not be more excited about the partnership, as it will further our capabilities to enable comprehensive decentralized trials with collection of in-home ECGs and remote evaluation of ECG reports when necessary.”
“At AliveCor, we are committed to making medical-grade ECG technology accessible no matter where a patient is,” said AliveCor CEO Priya Abani. “Removing barriers to the continuation of decentralized trials is yet another step in this direction. We look forward to partnering with Medable to progress this critical work.”
Today, there are more than 50,000 interventional clinical trials underway globally. Together, Medable and AliveCor aim to accelerate development of therapies by expanding research and improving convenience of trials.
Source: Company Press Release
